Soleno Therapeutics (SLNO) Non-Current Debt (2024 - 2026)

Soleno Therapeutics (SLNO) has 3 years of Non-Current Debt data on file, last reported at $49.9 million in Q1 2026.

• Quarterly Non-Current Debt changed 0.07% year-over-year to $49.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.9 million (changed 0.07% YoY) and the FY2025 annual result came in at $49.9 million, changed 0.07% from the prior year.
• Non-Current Debt steadied at $49.9 million in Q1 2026 per SLNO's latest filing, from $49.9 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $49.9 million in Q1 2026 and bottomed at $49.8 million in Q4 2024.
• The 3-year median for Non-Current Debt is $49.8 million (2025), against an average of $49.8 million.
• The widest annual swing landed in 2025, when Non-Current Debt increased 0.07%; it then gained 0.07% in 2026.
• Tracing SLNO's Non-Current Debt over 3 years: stood at $49.8 million in 2024, then increased by 0.07% to $49.9 million in 2025, then rose by 0.02% to $49.9 million in 2026.
• Per Business Quant, the three latest SLNO Non-Current Debt figures stand at $49.9 million (Q1 2026), $49.9 million (Q4 2025), and $49.9 million (Q3 2025).

Peer Comparison